Selective use of vandetanib in the treatment of thyroid cancer

Vandetanib is a once-daily orally available tyrosine kinase inhibitor that works by blocking RET (REarranged during Transfection), vascular endothelial growth factor receptor (VEGFR-2, VEGFR-3), and epidermal growth factor receptor and to a lesser extent VEGFR-1, which are important targets in thyro...

Descripción completa

Detalles Bibliográficos
Autores principales: Fallahi, Poupak, Di Bari, Flavia, Ferrari, Silvia Martina, Spisni, Roberto, Materazzi, Gabriele, Miccoli, Paolo, Benvenga, Salvatore, Antonelli, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498730/
https://www.ncbi.nlm.nih.gov/pubmed/26170630
http://dx.doi.org/10.2147/DDDT.S72495

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498730/
https://www.ncbi.nlm.nih.gov/pubmed/26170630
http://dx.doi.org/10.2147/DDDT.S72495

Ejemplares similares